John McCamant - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock John McCamant's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
John McCamant
Verified
Editor, Medical Technology Stock Letter
San Francisco
Beats
psychotherapy, trauma burnout collective trauma,political polarization effective communication, the media and trauma second-hand trauma, PTSD conflict resolution, trauma healing
Content
By John McCamant| MoneyShow@ We are recommending Skye Bioscience Inc. (SKYE) as our next investment opportunity in treating metabolic disease/obesity. Skye is developing a peripheral restricted CB1 antibody — nimacimab — to treat obesity by restoring leptin sensitivity and increasing fat metabolism, while avoiding the CB1-induced THC/neuro side effects, says John McCamant, editor of Medical Technology Stock Letter.
By John McCamant| MoneyShow@ Madrigal Pharmaceuticals Inc. (MDGL) is our top conservative biotech recommendation for 2025. The company is in the sweet spot and de-risked with the first FDA-approved drug for chronic liver inflammation/NASH, suggests John McCamant, editor of Medical Technology Stock Letter. MDGL’s recently approved pill is called Rezdiffra and it had a very strong 3Q.
By John McCamant| MoneyShow@ We are recommending Skye Bioscience Inc. (SKYE) as our next investment opportunity in treating metabolic disease/obesity. Skye is developing a peripheral restricted CB1 antibody — nimacimab — to treat obesity by restoring leptin sensitivity and increasing fat metabolism, while avoiding the CB1-induced THC/neuro side effects, says John McCamant, editor of Medical Technology Stock Letter.
Company Info
Medical Technology Stock Letter
For more than 30 years, the Medical Technology Stock Letter (MTSL) has provided independent investment advice based on rigorous analysis of emerging biotechnology companies and a unique perspective on industry fundamentals. MTSL has a proven track record of identifying many of today's industry leaders well before the consensus of other analysts.
San Francisco, United States
+1 510-843-1857